Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model

• Published in: Cellular oncology (Dordrecht) Vol. 47; no. 5; pp. 1735 - 1756
• Main Authors: Mashhouri, Siavash, Rahmati, Amirhossein, Azimi, Ako, Fava, Roy A., Ismail, Ismail Hassan, Walker, John, Elahi, Shokrollah
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2024
• Subjects: Animals; beta-Glucans - pharmacology; Biomedical and Life Sciences; Biomedicine; Cancer Research; Cell Line, Tumor; Colorectal Neoplasms - genetics; Colorectal Neoplasms - immunology; Colorectal Neoplasms - metabolism; Colorectal Neoplasms - pathology; Disease Models, Animal; Humans; Lectins, C-Type - metabolism; Melanoma - immunology; Melanoma - pathology; Melanoma, Experimental - immunology; Melanoma, Experimental - pathology; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells - drug effects; Myeloid Cells - immunology; Myeloid Cells - metabolism; Oncology; Pathology; Signal Transduction - drug effects; Tumor Microenvironment - drug effects; Tumor Microenvironment - immunology; Dectin-1 KO mice; Dectin-1+ T cells; Dectin-1+ Myeloid cells; PD-L1+Dectin-1+ myeloid cells; VISTA KO mice
• ISSN: 2211-3428; 2211-3436; 2211-3436
• DOI: 10.1007/s13402-024-00950-w

Purpose Acquired resistance to immune checkpoint blockers (ICBs) is a major barrier in cancer treatment, emphasizing the need for innovative strategies. Dectin-1 (gene Clec7a ) is a C-type lectin receptor best known for its ability to recognize β-glucan-rich structures in fungal cell walls. While Dectin-1 is expressed in myeloid cells and tumor cells, its significance in cancer remains the subject of controversy. Methods Using Celc7a-/- mice and curdlan administration to stimulate Dectin-1 signaling, we explored its impact. VISTA KO mice were employed to assess VISTA’s role, and bulk RNAseq analyzed curdlan effects on neutrophils. Results Our findings reveal myeloid cells as primary Dectin-1 expressing cells in the tumor microenvironment (TME), displaying an activated phenotype. Strong Dectin-1 co-expression/co-localization with VISTA and PD-L1 in TME myeloid cells was observed. While Dectin-1 deletion lacked protective effects, curdlan stimulation significantly curtailed B16-F10 tumor progression. RNAseq and pathway analyses supported curdlan’s role in triggering a cascade of events leading to increased production of pro-inflammatory mediators, potentially resulting in the recruitment and activation of immune cells. Moreover, we identified a heterogeneous subset of Dectin-1+ effector T cells in the TME. Similar to mice, human myeloid cells are the prominent cells expressing Dectin-1 in cancer patients. Conclusion Our study proposes Dectin-1 as a potential adjunctive target with ICBs, orchestrating a comprehensive engagement of innate and adaptive immune responses in melanoma. This innovative approach holds promise for overcoming acquired resistance to ICBs in cancer treatment, offering avenues for further exploration and development.